Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan-eluting beads - Biocompatibles

Next Previous
X
Search
Drug Profile

Irinotecan-eluting beads - Biocompatibles

Alternative Names: CM-BC2; DEBIRI; Irinotecan bead; Irinotecan-loaded DC Bead LUMI™; Irinotecan-loaded DC BeadM1™; Irinotecan-loaded DC Bead™; PARAGON Bead

Latest Information Update: 17 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocompatibles International
  • Developer Biocompatibles International; BTG; Singapore General Hospital
  • Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Liver metastases
  • Phase II Cholangiocarcinoma
  • Phase I/II Glioma

Most Recent Events

  • 17 Dec 2020 BTG International terminates a phase I/II trial in Glioma (Adjunctive treatment, Recurrent) in Germany and France based on the slow rate of recruitment across the programme of studies (NCT02481960)
  • 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
  • 19 Oct 2018 Safety and efficacy data from a phase II trial in Colorectal cancer with liver metastases presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018) (NCT01839877)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top